ENHERTU (fam-trastuzumab deruxtecan-nxki), jointly developed by Daiichi Sankyo and AstraZeneca, has received two additional Breakthrough Therapy Designations (BTDs) in the United States.

#breakthrough #USFDA #breastcancer #cancer #pharma #astrazeneca #oncology

If you like the content, pls feel free to support me: https://buymeacoffee.com/pharmanews